Identification of Genetic Targets in Gynecological Tumors Via a Triple in Silico Ex-vivo / in Vivo Approach
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This observational study aims to identfy genetic targets involved in the pathogenesis of gynecological tumors, with a focus on high-grade serous ovarian carcinoma. Using a triple approach - in silico, ex vivo and in vitro - the study will investigate the role of gonadotropins and their related signaling pathways in the epithelial ovarian cancers. Gene and protein expression levels will be evaluated through transcriptomic analysis, immunohistochemistry and functional assays on tumor cell lines. The goal is to uncover potential diagnostic or therapeutic targets in gynecological malignancies.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult women ≥18 years old
• Histologically confirmed diagnosis of epithelial ovarian cancer (including high- grade serous, endometrioid, mucinous, clear cell, or mesonephric-like histotypes)
• Signed informed consent (for prospective cases) or ethically approved waiver (for retrospective samples)
Locations
Other Locations
Italy
Azienda USL IRCCS di Reggio Emilia
RECRUITING
Reggio Emilia
Contact Information
Primary
Beatrice Melli, MD
beatrice.melli@ausl.re.it
0522-29577
Time Frame
Start Date:2021-11-17
Estimated Completion Date:2027-11
Participants
Target number of participants:180
Treatments
Ovarian Cancer
Participants with high-grade serous ovarian carcinoma (HGSOC) or other rare epithelial ovarian tumor subtypes (e.g., mucinous, endometrioid, clear cell, mesonephric-like). Includes both prospectively enrolled patients and retrospectively collected samples. Purpose: to analyze gene and protein expression profiles in tumor tissues and compare them with normal ovarian epithelium.
Control group
Patients undergoing surgery for benign gynecological conditions, from whom non-tumoral ovarian epithelial tissue is obtained. Purpose: to provide baseline biological controls for comparison with ovarian cancer samples.